The purpose of this research study is to determine if testing on blood and tissue samples, and analysis of PET/CT scans, can help researchers determine which patients are more or less likely to respond to treatment with anti-PD1 immunotherapy. Current drugs in this category include pembrolizumab and nivolumab. In the future, this information may help physicians better tailor treatment plans for their patients.
UW16032 – Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
This project was funded by: NIH
The term of this project was: January 2018 to November 2018
The number of subjects scanned during this project was: 4